India’s Sun Pharmaceutical Industries reported a 27% rise in quarterly profit on Friday, boosted by strong demand for its high-margin specialty medicines used to treat chronic and complex conditions.
Financial Performance
Consolidated net profit rose to 28.95 billion rupees ($303.54 million) in the quarter ended June 30 from 22.79 billion rupees a year earlier. The specialty segment accounted for 21.9% of total revenue, with sales rising 12.8% to $351 million, supported by 16% growth in India, the company’s largest market.
Overall revenue rose 10.5% to 153 billion rupees. Sun Pharma has been expanding in higher-margin specialty medicines, including treatments for skin disease, cancer, and obesity, to offset pressure in its U.S. business.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
